SubHero Banner

Lynparza® (olaparib) – New indication

December 30, 2019 - AstraZeneca and Merck announced the FDA approval of Lynparza (olaparib), for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

Download PDF